It does raise the issue of full disclosure. The company will...

It does raise the issue of full disclosure. The company will know the results of every patient and they along with the labs will effectively be sitting on vital information during 2016. Its hard to imagine how this information cannot be leaked. If you knew that SVR had been achieved and prior and ongoing monitoring showed a sustained action, you would not be waiting for the end of trial to buy the stock. Even now they may have this information.